- **Avant Technologies Inc. announced a pivotal evolution in its business direction**, emphasizing strategic partnerships through joint ventures and licensing agreements to advance treatments for chronic and age-related conditions.  **[1740797_20250925LN83229:0]** 
- This new model focuses on **collaborative biotech innovation**, identifying promising cell lines and forging alliances with leading biotech companies, scientists, and clinicians.  **[1740797_20250925LN83229:0]** 
- Key areas of focus for these collaborations include **diabetes, anti-aging, Alzheimer's disease, heart disease, cancer, and kidney disease**.  **[1740797_20250925LN83229:0]** 
- The company has applied for a **corporate name change** to better reflect its focus on pioneering biotechnology collaborations.  **[1740797_20250925LN83229:0]** 
- Avant's first joint venture is with **Ainnova Tech, Inc.**, for AI-driven diagnostics, and a recent joint venture focuses on developing a cell line therapy that produces the **Klotho protein**.  **[1740797_20250925LN83229:0]**

Avant Technologies Announces Strategic Shift to Biotech Partnerships

- **Avant Technologies** (OTCQB: AVAI), Art-Islets Pte. Ltd., and Austrianova (SGAustria Pte. Ltd.) have formed a **Joint Venture and License Agreement** to revolutionize diabetes treatment through innovative stem cell and encapsulation technologies.  **[1740797_20250924LN82095:0]** 
- The collaboration aims to research, develop, manufacture, and commercialize advanced therapies for **type 1 and insulin-dependent type 2 diabetes** patients worldwide.  **[1740797_20250924LN82095:0]** 
- **Avant Technologies** will provide **initial funding over the next eight months** to achieve the first three milestones and will leverage its resources to secure further funding for a potential Phase 1 clinical trial.  **[1740797_20250924LN82095:0]** 
- Art-Islets contributes its proprietary **"differentiation system"** for transforming ESCs into insulin-producing cells, and Austrianova provides its proprietary **cell-encapsulation technology**.  **[1740797_20250924LN82095:0]**

Avant Technologies Forms Joint Venture for Diabetes Treatment

- **Avant Technologies Inc.** (OTCQB: AVAI) and Austrianova have established **Klothonova, Inc.**, a new Nevada corporation, as a **50/50 joint venture** through a Joint Venture and License Agreement.  **[1740797_20250918LN76844:0]** 
- Klothonova will focus on pioneering **cell-based therapies** utilizing encapsulated Klotho-producing cells to develop treatments for Alzheimer's disease, heart disease, cancer, kidney disease, other age-related conditions, and longevity promotion.  **[1740797_20250918LN76844:0]** 
- Austrianova will contribute its proprietary cell encapsulation technology, intellectual property, and 'know-how', while Avant Technologies will provide **capital and additional resources** to support Klothonova's operations.  **[1740797_20250918LN76844:0]**

Avant Technologies and Austrianova Form Joint Venture for Klotho-Based Therapies

- AVANT TECHNOLOGIES INC. (AVAI) and SGAustria Pte. Ltd. (Austrianova) entered into a Joint Venture & License Agreement on **September 15, 2025**, to establish a new Nevada Corporation named **Klothonova, Inc.**.  **[1740797_0001740797-25-000047_exhibit10_1.htm:0]** **[1740797_0001740797-25-000047_form8_avai.htm:1]** 
- Klothonova's primary objective is to develop, maintain, and support treatments for various medical conditions, including **Alzheimer's disease, heart disease, cancer, kidney disease, and other age-related conditions**, by utilizing encapsulated Klotho-producing cells.  **[1740797_0001740797-25-000047_exhibit10_1.htm:3]** 
- AVAI will contribute up to **$1.5 million USD** in capital for Klothonova's formation and operation over the next **eighteen months**, with the potential for an additional **$8.5 million USD** in follow-up financing as a loan.  **[1740797_0001740797-25-000047_exhibit10_1.htm:0]** **[1740797_0001740797-25-000047_form8_avai.htm:1]** **[1740797_0001740797-25-000047_exhibit10_1.htm:3]** **[1740797_0001740797-25-000047_exhibit10_1.htm:4]** 
- The ownership of Klothonova will be equally split, with **50%** held by AVAI and **50%** by Austrianova, each possessing **1,500,000 shares** of common stock.  **[1740797_0001740797-25-000047_exhibit10_1.htm:0]** **[1740797_0001740797-25-000047_form8_avai.htm:1]** **[1740797_0001740797-25-000047_exhibit10_1.htm:3]** 
- Austrianova will grant an **exclusive license** for its proprietary cell encapsulation technology to Klothonova for the development of these treatments.  **[1740797_0001740797-25-000047_exhibit10_1.htm:3]**

AVANT TECHNOLOGIES (AVAI)